{"id":"W4281784552","doi":"10.1200/jco.2022.40.16_suppl.7539","title":"Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Five-year follow-up of ELEVATE-TN.","year":2022,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Chronic Lymphocytic Leukemia Research","field":"Medicine","cited_by":26,"is_retracted":false,"has_abstract":true,"ca_institutions":"University of Manitoba; CancerCare Manitoba","funders":"","keywords":"Chlorambucil; Medicine; Obinutuzumab; Internal medicine; Gastroenterology; Hazard ratio; Chronic lymphocytic leukemia; Leukemia; Chemotherapy; Confidence interval; Cyclophosphamide","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.002657732,0.0005198222,0.001280725,0.0003190414,0.0003673729,0.0006957979,0.0005129581,0.0005963944,0.001954893],"category_scores_gemma":[0.001077351,0.0002066653,0.001300547,0.0004651838,0.0003502152,0.0006788296,0.0003189508,0.001342494,0.000415533],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.001053851,"about_ca_system_score_gemma":0.0008225557,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001826558,"about_ca_topic_score_gemma":0.0033733,"domain_scores_codex":[0.9994038,0.0002297047,0.00005051591,0.000100283,0.0000766409,0.0001390251],"domain_scores_gemma":[0.9990902,0.0001677185,0.0003056682,0.00006832879,0.00005395657,0.0003142021],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.8277143,0.01702904,0.04288687,0.0005081117,0.00332245,0.0001859429,0.0002290959,0.001388079,0.009759993,0.0001334111,0.002865036,0.09397774],"study_design_scores_gemma":[0.2719773,0.4950517,0.215681,0.0001390747,0.004802291,0.0004493798,0.0001498888,0.002259582,0.004030079,0.000271841,0.005133626,0.00005422222],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9943763,0.002695922,0.0001790384,0.0001168227,0.00004135171,0.0004063201,0.001071892,0.00002341102,0.001088903],"genre_scores_gemma":[0.9954109,0.000946885,0.0002116581,0.0002933838,0.00006655395,0.0003022601,0.001961795,0.000005891275,0.0008006993],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.002657732,"threshold_uncertainty_score":0.01405555,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.1304341276877111,"score_gpt":0.4440959052532594,"score_spread":0.3136617775655482,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}